Drugs / DA-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06648850 | May 2026 → Mar 2027 expected | baldness, male pattern, telogen effluvium | Applied Biology, Inc. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06484881 | Sep → Oct 2024 | androgenetic alopecia | Applied Biology, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-001 | “DA-001 is a botanical supplement demonstrated natural ingredients known to exert anti-androgen effects.” NCT06484881 ↗1“DA-001 Topical” NCT06648850 ↗ |
| Action | Activate | “DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist.” NCT06648850 ↗ |
| Route | Oral | “as an oral supplement” NCT06484881 ↗ |